


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSILICO MEDICINE

InSilico Medicine Cayman TopCo

英矽智能

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3696)

VOLUNTARY ANNOUNCEMENT INCLUSION AS A CONSTITUENT OF HANG SENG BIOTECH INDEX

This announcement is made by InSilico Medicine Cayman TopCo (the “**Company**”, together with its subsidiaries, the “**Group**” or “**InSilico Medicine**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that, according to the index review results of Hang Seng Indexes Company Limited for the first quarter of 2026, InSilico Medicine will be included as a constituent stock of the Hang Seng Biotech Index. The inclusion will be implemented after market close on June 5, 2026 (Friday) and will take effect on June 8, 2026 (Monday). The Hang Seng Biotech Index reflects the overall performance of the 30 largest biotech companies that are listed in Hong Kong and tradable under the Southbound Stock Connect.

The Board believes that the Company’s inclusion as a constituent of the Hang Seng Biotech Index reflects the capital market’s recognition of and confidence in the Company’s long-term growth potential. Moreover, this milestone is anticipated to introduce the Company’s shares to a broader range of index funds and core portfolios of institutional investors, which will help diversify the investor base, boost trading liquidity, and enhance resilience against risks.

The Board appreciates the continued support from the shareholders and investors of the Company.

Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO

Hong Kong, May 26, 2026

As at the date of this announcement, the Board comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Kan Chen, Ph.D., Mr. Chuen Yan Leung, Ph.D., and Mr. Long Shi as non-executive directors; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.